Skip to content

What is the Role of Type III/IV Muscle Afferents in Airway Resistance and Thermoregulatory Responses to Exercise?

Type III/IV Muscle Afferents in Airway and Thermoregulatory Responses

Status
Not yet recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07452094
Enrollment
15
Registered
2026-03-05
Start date
2026-04-01
Completion date
2027-04-01
Last updated
2026-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Experimental, Placebo - Control

Keywords

Group III/IV afferents, exercise, thermoregulation, sweating, blood flow, airway resistance

Brief summary

Exercise places serious demands on the body. These demands are fundamentally caused by increases in oxygen demand and the consequent increase in body temperature. These demands are met by several physiological responses, including increases in heart rate, blood pressure, breathing and blood flow. These responses must be proportional to the increase in demand and some signal must relay information from the muscle to the brain. Group III/IV afferents do just this. They relay information about the muscle (movement, temperature, acidity, etc.) up to the brain so that appropriate responses are mounted. There is strong evidence in animals that group III/IV afferents play a key role in making breathing easier (decreasing airway resistance) and initiating sweating and blood flow responses. There has been no research on the role of group III/IV afferents on these fundamental exercise responses in humans. The investigators propose to isolate the role of group III/IV afferents on regulate airway resistance, sweating and blood flow responses to exercise in humans.

Detailed description

Group III/IV afferents are nerves that relay information from the muscles to the central nervous system. This afferent activity acts as negative feedback to minimize the overall strain placed on muscles . Without this negative feedback, locomotor muscles become damaged during intense exercise. It is well-established that group III/IV afferents are required for normal breathing and blood pressure responses to physical activity. In certain disease states, such as chronic obstructive pulmonary disease, heart failure and hypertension, group III/IV afferents become dysfunctional and lead to exercise intolerance. This is a major issue in these patient groups where regular exercise is advocated to slow or halt disease progression. Understanding how these reflexes contribute to basic cardiorespiratory responses to exercise is thus warranted. At the onset of exercise, there is a near instantaneous decrease in airway resistance that permits high rates of breathing ; these high rates of breathing are essential to ensure appropriate oxygen transport to working muscles. The decrease in airway resistance is facilitated by a rapid withdrawal of parasympathetic tone to the smooth muscle lining the airways, allowing them to open up and remain rigid. Evidence in cats and dogs indicate that group III/IV afferents reflexively contribute to this response, thereby coupling airway dilation to muscle work. Airway resistance can be quantified by measuring the work required by breathing muscles to pull air into and push air out of the lungs. If the magnitude of airway dilation changes due to the suppression of group III/IV afferents, the investigators would observe a compensatory increase in how much work is required to overcome resistance. This has not been investigated directly in humans. Alongside the fundamental cardiorespiratory responses to exercise, humans mount powerful thermoregulatory responses that dissipate heat generated from muscle work. The primary thermoregulatory responses in humans are eccrine sweating and skin vasodilation; both of which are activated as body temperature rises. Exercise augments thermoregulatory responses to heating, and sweating is initiated within 1-2 seconds of initiating exercise despite body temperature remaining stable. Thus, there is clearly a link between muscular work and thermoregulation. Reduced preparations in cats have shown that group III/IV afferent activity is elevated during external muscle heating, and human sweating responses are more closely coupled to muscle temperature than to core or skin temperature. To date, no study in humans has tried to isolate the role of group III/IV afferents on thermoregulatory responses to exercise. These group III/IV afferents can be studied in exercising humans by suppressing their activity using intrathecal (spinal) opioids. Simply, a subject exercises on two different occasions, one with intact muscle reflex feedback, and the other with the feedback suppressed; differences in exercise responses are isolated to the role of group III/IV afferents. The investigators aim to use this model to quantify the contribution of group III/IV afferent reflexes to airway resistance, sweating and skin vasodilation.

Interventions

DRUGEXERCISE TRAINING WITH OR WITHOUT MEDICATION

Cycling exercise with group III/IV afferent feedback blocked via drug

Sponsors

Northern Arizona University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Participant will be blinded to condition. Researcher will be blinded to condition. Researcher will be masked to data during analysis.

Intervention model description

Randomized order, repeated measures, cross-over

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* regularly physically active as determined via questionnaires (Par-Q \& You) * maximal aerobic power 30 mL/min/kg (female), 40 mL/kg/min (male)

Exclusion criteria

* current smokers * acute bronchial asthma * diabetics * chronic back pain * peripheral neuropathy * chronic obstructive airway or status asthmaticus * obese (body mass index \> 30 kg/m2) * convulsive disorders * requiring daily medications that may affect responses to exercise (e.g. anti-hypertensive, anti-arrhythmogenics, blood thinners) * history of drug abuse * history of disease/dysfunction that could cause complication with exercise (e.g. cardiovascular, respiratory, neurological, musculoskeletal) * irregular or absent menstrual cycle * pregnant or suspected pregnancy * adverse response to physical exercise * current or history of esophageal or gastric disease, or frequent heart burn (\>2x per week) * Lidocaine allergy

Design outcomes

Primary

MeasureTime frameDescription
Airway resistance2 weeksCalculated based of work of breathing and ventilation flow rate
Sweat rate2 weeksLocal eccrine sweat rates at 3 different sites
Skin blood flow2 weeksSkin blood flux measured at different skin sites

Countries

United States

Contacts

CONTACTTRAVIS D GIBBONS, PhD
travis.gibbons@nau.edu19282558769
PRINCIPAL_INVESTIGATORTRAVIS D GIBBONS, PhD

Northern Arizona University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026